Elimination of alloantibodies by immunoablative high-dose cyclophosphamide

Robert A. Brodsky, Alice K. Fuller, Lloyd E. Ratner, Mary S. Leffell, Richard J. Jones

Research output: Contribution to journalArticlepeer-review

Abstract

Background. Alloimmunization is a major problem for patients being considered for solid organ transplantation and in patients who require blood transfusion support. We previously demonstrated that high-dose cyclophosphamide (200 mg/kg) without hematopoietic stem cell transplantation leads to durable complete remissions in aplastic anemia and other autoimmune disorders. We now examine the ability of high-dose cyclophosphamide to eliminate alloreactivity. Methods. IgG-specific antibodies to HLA class I were assayed using enzyme-linked immunosorbent assays in 18 consecutive patients with severe aplastic anemia before and after treatment with high-dose cyclophosphamide. Results. Anti-HLA antibodies were detected before or shortly after therapy in 5 of the 18 patients studied. Complete remission of aplastic anemia was achieved in four of these five patients. High-dose cyclophosphamide markedly reduced anti-HLA antibody titers in these four patients; they were completely eradicated in three patients. Only one patient did not achieve significant reduction in the alloantibody liter after high-dose cyclophosphamide. Conclusions. High-dose cyclophosphamide without stem cell transplantation can eradicate HLA-specific alloantibody.

Original languageEnglish (US)
Pages (from-to)482-484
Number of pages3
JournalTransplantation
Volume71
Issue number3
DOIs
StatePublished - Feb 15 2001

ASJC Scopus subject areas

  • Transplantation

Fingerprint Dive into the research topics of 'Elimination of alloantibodies by immunoablative high-dose cyclophosphamide'. Together they form a unique fingerprint.

Cite this